Enoch C Choi, MD
Family Practice · Gilroy
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 6
- 3 carriers
- Offices
- 6
Offices
6 locations · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
6 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Choi’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
6 of 6 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A65324 · Current
Licensed to practise in California · since 1998 · expires 2028-05-31 · Brown University Program in Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$991,400 in 2024
Medicaid paid $991,400 for 14,073 billed services this clinician did in 2024, up to 214 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,593 | $987,255 |
| Return visit (30+ min) | 662 | $1,338 |
| Short return visit | 1,274 | $1,112 |
| Short return visit (20+ min) | 713 | $983 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 160 | $447 |
| New patient visit (30+ min) | 49 | $149 |
| New patient visit (45+ min) | 19 | $98 |
| URINE PREGNANCY TEST | 92 | $15 |
| Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use | 53 | $5 |
| Pain severity quantified; pain present (COA) (ONC) | 436 | $0 |
| Pain severity quantified; no pain present (COA) (ONC) | 348 | $0 |
| Medication list documented in medical record (COA) | 1,917 | $0 |
| 2024 | 14,073 | 19 | 214 | $991,400 |
| 2023 | 22,402 | 22 | 712 | $3,013,306 |
| 2022 | 22,939 | 19 | 632 | $2,898,869 |
| 2021 | 15,400 | 16 | 408 | $2,151,185 |
| 2020 | 7,804 | 9 | 340 | $719,490 |
| 2019 | 4,292 | 12 | 216 | $426,305 |
| 2018 | 1,371 | 13 | 54 | $20,466 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 4,954 | $2,969,030 |
| Return visit (30+ min) | 6,752 | $32,895 |
| Short return visit (20+ min) | 2,180 | $6,152 |
| New patient visit (30+ min) | 324 | $2,348 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 25 | $965 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 24 | $954 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 57 | $200 |
| URINE PREGNANCY TEST | 536 | $183 |
| Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected | 13 | $180 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 26 | $173 |
| Short return visit | 56 | $137 |
| Injection, ceftriaxone sodium, per 250 mg | 15 | $28 |
2022
| Clinic visit/encounter, all-inclusive | 4,901 | $2,849,619 |
| Return visit (30+ min) | 6,542 | $36,526 |
| Short return visit (20+ min) | 2,583 | $10,851 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 15 | $770 |
| Short return visit | 180 | $702 |
| URINE PREGNANCY TEST | 658 | $299 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 12 | $43 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 173 | $27 |
| Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use | 51 | $25 |
| Injection, ceftriaxone sodium, per 250 mg | 13 | $7 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 574 | $0 |
| Most recent hemoglobin A1c (HbA1c) level greater than or equal to 7.0% and less than 8.0% (DM) | 17 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 4,081 | $2,125,814 |
| Return visit (30+ min) | 3,543 | $14,479 |
| Short return visit (20+ min) | 2,902 | $7,546 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 40 | $2,052 |
| Short return visit | 436 | $1,069 |
| URINE PREGNANCY TEST | 509 | $182 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 280 | $41 |
| Blood glucose (sugar) level | 43 | $3 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 251 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 1,054 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 287 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 305 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 2,913 | $701,871 |
| Short return visit (20+ min) | 2,542 | $7,760 |
| Return visit (30+ min) | 1,623 | $6,492 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 33 | $1,693 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 106 | $886 |
| Short return visit | 259 | $706 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 209 | $57 |
| URINE PREGNANCY TEST | 55 | $25 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 64 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 1,610 | $411,146 |
| Return visit (30+ min) | 1,316 | $6,605 |
| Service | 85 | $2,899 |
| Short return visit (20+ min) | 784 | $2,179 |
| New patient visit (45+ min) | 171 | $1,689 |
| New patient visit (30+ min) | 117 | $1,188 |
| Long return visit (40+ min) | 27 | $231 |
| Short return visit | 44 | $121 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 13 | $110 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 27 | $58 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 12 | $52 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 86 | $27 |
2018
| Service | 269 | $9,139 |
| New patient visit (45+ min) | 356 | $8,234 |
| New patient visit (30+ min) | 213 | $1,309 |
| Return visit (30+ min) | 271 | $957 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 42 | $362 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 41 | $141 |
| Service | 37 | $134 |
| ELECTROLYTE PANEL | 12 | $87 |
| Short return visit (20+ min) | 68 | $53 |
| Blood glucose (sugar) level | 25 | $43 |
| Creatinine; blood | 12 | $5 |
| Urea nitrogen; quantitative | 12 | $2 |
Drugs they prescribed that Part D paid
$11,648
Pharmacies billed $11,648 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
338 generic and fewer than 11 brand-name prescriptions · $11,648 in drug cost · 83 antibiotic prescriptions to 72 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Albuterol Sulfate Hfa | 12 | $433 | $36 |
| Nitrofurantoin Mono-Macro | 14 | $164 | $12 |
| Ibuprofen | 38 | $143 | $4 |
| Cephalexin | 22 | $114 | $5 |
| Amoxicillin-Clavulanate Potass | 15 | $109 | $7 |
See all 9 drugs
| Albuterol Sulfate Hfa | 12 | $433 | $36 |
| Nitrofurantoin Mono-Macro | 14 | $164 | $12 |
| Ibuprofen | 38 | $143 | $4 |
| Cephalexin | 22 | $114 | $5 |
| Amoxicillin-Clavulanate Potass | 15 | $109 | $7 |
| Atorvastatin | 13 | $53 | $4 |
| Omeprazole | 11 | $51 | $5 |
| Amlodipine Besylate | 11 | $35 | $3 |
| Paxlovid | 13 | $0 | $0 |
Year by year
| 2024 | 405 | 215 | None | None | $11,648 |
| 2023 | 389 | 198 | None | 11% | $15,166 |
| 2022 | 431 | 243 | None | 16% | $17,079 |
| 2021 | 326 | 197 | None | 10% | $7,467 |
| 2020 | 225 | 130 | None | 13% | $6,840 |
| 2019 | 272 | 164 | None | None | $19,889 |
| 2018 | 153 | 86 | None | None | $4,630 |
| 2017 | 291 | 166 | 4% (11) | 13% | $10,406 |
| 2016 | 269 | 141 | 4% (11) | None | $9,591 |
| 2015 | 362 | 166 | 4% (15) | None | $27,143 |
| 2014 | 259 | 151 | 5% (12) | None | $14,100 |
| 2013 | 311 | 191 | 11% (34) | None | $9,571 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Albuterol Sulfate Hfa | 12 | $503 | $42 |
| Cephalexin | 21 | $271 | $13 |
| Montelukast | 11 | $196 | $18 |
| Fluticasone Propionate | 12 | $187 | $16 |
| Ibuprofen | 32 | $154 | $5 |
| Paxlovid (Eua) | 12 | $132 | $11 |
| Omeprazole | 11 | $109 | $10 |
| Amlodipine Besylate | 13 | $93 | $7 |
| Cyclobenzaprine | 11 | $84 | $8 |
2022: 9 drugs
| Albuterol Sulfate Hfa | 17 | $780 | $46 |
| Cephalexin | 27 | $198 | $7 |
| Nitrofurantoin Mono-Macro | 11 | $164 | $15 |
| Gabapentin | 11 | $114 | $10 |
| Fluticasone Propionate | 13 | $105 | $8 |
| Paxlovid (Eua) | 11 | $84 | $8 |
| Omeprazole | 14 | $83 | $6 |
| Ibuprofen | 20 | $73 | $4 |
| Amlodipine Besylate | 11 | $50 | $5 |
2021: 5 drugs
| Cephalexin | 33 | $246 | $7 |
| Fluticasone Propionate | 15 | $161 | $11 |
| Amlodipine Besylate | 17 | $140 | $8 |
| Amoxicillin-Clavulanate Potass | 11 | $105 | $10 |
| Ibuprofen | 17 | $65 | $4 |
2020: 3 drugs
| Azelastine | 11 | $462 | $42 |
| Cephalexin | 11 | $51 | $5 |
| Ibuprofen | 12 | $46 | $4 |
2019: 4 drugs
| Ventolin Hfa | 11 | $607 | $55 |
| Cephalexin | 16 | $88 | $6 |
| Ciprofloxacin | 14 | $78 | $6 |
| Ibuprofen | 14 | $55 | $4 |
2018: 1 drug
| Lisinopril | 11 | $68 | $6 |
2017: 8 drugs
| Proair Hfa | 12 | $688 | $57 |
| Doxycycline Hyclate | 25 | $530 | $21 |
| Fluticasone Propionate | 16 | $234 | $15 |
| Bupropion Hcl Sr | 12 | $147 | $12 |
| Azithromycin | 20 | $91 | $5 |
| Cephalexin | 11 | $67 | $6 |
| Hydrocodone-Acetaminophen | 11 | $34 | $3 |
| Prednisone | 11 | $28 | $3 |
2016: 5 drugs
| Fluticasone Propionate | 19 | $240 | $13 |
| Atorvastatin | 12 | $177 | $15 |
| Omeprazole | 14 | $152 | $11 |
| Amoxicillin-Clavulanate Potass | 11 | $138 | $13 |
| Azithromycin | 12 | $79 | $7 |
2015: 8 drugs
| Azelastine | 17 | $1,152 | $68 |
| Proair Hfa | 18 | $1,025 | $57 |
| Fluticasone Propionate | 15 | $165 | $11 |
| Azithromycin | 15 | $126 | $8 |
| Amlodipine Besylate | 11 | $97 | $9 |
| Ciprofloxacin | 12 | $73 | $6 |
| Lisinopril | 13 | $71 | $5 |
| Hydrocodone-Acetaminophen | 13 | $58 | $4 |
2014: 5 drugs
| Proair Hfa | 11 | $541 | $49 |
| Fluticasone Propionate | 13 | $197 | $15 |
| Azithromycin | 17 | $122 | $7 |
| Triamcinolone Acetonide | 11 | $85 | $8 |
| Lisinopril | 12 | $63 | $5 |
2013: 8 drugs
| Fluticasone Propionate | 28 | $999 | $36 |
| Levofloxacin | 17 | $242 | $14 |
| Hydrocodone-Acetaminophen | 29 | $169 | $6 |
| Azithromycin | 17 | $156 | $9 |
| Cephalexin | 15 | $124 | $8 |
| Ciprofloxacin | 13 | $82 | $6 |
| Sulfamethoxazole-Trimethoprim | 11 | $67 | $6 |
| Prednisone | 14 | $58 | $4 |
Professional record
- NPI
- 1215039185
- Licence
- CA A65324California A65324: Current · expires 2028-05-31
- Trained
- Warren Alpert Medical School of Brown University, 1996
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 2350 W El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2006-09-02
- NPI last updated
- 2012-01-09
This is when the NPI record was last certified, not a medical board exam.